The discovery of TAS2R9 as a CAF-selective marker whose targeting can improve the anti-tumor effects of liposomal delivery of a CXCR2 inhibitor opens the door for the modulation of CAF activity as a potent therapeutic strategy in PDAC. This evidence concerns the gene TAS2R9 and neoplasm.